Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109474061> ?p ?o ?g. }
- W2109474061 endingPage "2626" @default.
- W2109474061 startingPage "2618" @default.
- W2109474061 abstract "Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF deterioration despite therapies with angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and even an aldosterone antagonist. To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases cardiovascular mortality, morbidity, and all-cause mortality in patients with CHF and depressed LVEF, a prespecified analysis of the combined Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) low LVEF trials was performed. CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program. Methods and Results— New York Heart Association (NYHA) class II through IV CHF patients with an LVEF of ≤40% were randomized to candesartan or placebo in 2 complementary parallel trials (CHARM-Alternative, for patients who cannot tolerate ACE inhibitors, and CHARM-Added, for patients who were receiving ACE inhibitors). Mortality and morbidity were determined in 4576 low LVEF patients (2289 candesartan and 2287 placebo), titrated as tolerated to a target dose of 32 mg once daily, and observed for 2 to 4 years (median, 40 months). The primary outcome (time to first event by intention to treat) was cardiovascular death or CHF hospitalization for each trial, with all-cause mortality a secondary end point in the pooled analysis of the low LVEF trials. Of the patients in the candesartan group, 817 (35.7%) experienced cardiovascular death or a CHF hospitalization as compared with 944 (41.3%) in the placebo group (HR 0.82; 95% CI 0.74 to 0.90; P <0.001) with reduced risk for both cardiovascular deaths (521 [22.8%] versus 599 [26.2%]; HR 0.84 [95% CI 0.75 to 0.95]; P =0.005) and CHF hospitalizations (516 [22.5%] versus 642 [28.1%]; HR 0.76 [95% CI 0.68 to 0.85]; P <0.001). It is important to note that all-cause mortality also was significantly reduced by candesartan (642 [28.0%] versus 708 [31.0%]; HR 0.88 [95% CI 0.79 to 0.98]; P =0.018). No significant heterogeneity for the beneficial effects of candesartan was found across prespecified and subsequently identified subgroups including treatment with ACE inhibitors, β-blockers, an aldosterone antagonist, or their combinations. The study drug was discontinued because of adverse effects by 23.1% of patients in the candesartan group and 18.8% in the placebo group; the reasons included increased creatinine (7.1% versus 3.5%), hypotension (4.2% versus 2.1%), and hyperkalemia (2.8% versus 0.5%), respectivelyt (all P <0.001). Conclusion— Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF ≤40% when added to standard therapies including ACE inhibitors, β-blockers, and an aldosterone antagonist. Routine monitoring of blood pressure, serum creatinine, and serum potassium is warranted." @default.
- W2109474061 created "2016-06-24" @default.
- W2109474061 creator A5006688566 @default.
- W2109474061 creator A5008402827 @default.
- W2109474061 creator A5014449865 @default.
- W2109474061 creator A5018419311 @default.
- W2109474061 creator A5020758622 @default.
- W2109474061 creator A5022837719 @default.
- W2109474061 creator A5027213857 @default.
- W2109474061 creator A5028660133 @default.
- W2109474061 creator A5031560506 @default.
- W2109474061 creator A5037002715 @default.
- W2109474061 creator A5037320109 @default.
- W2109474061 creator A5054163944 @default.
- W2109474061 creator A5054830306 @default.
- W2109474061 creator A5064737068 @default.
- W2109474061 creator A5077729845 @default.
- W2109474061 creator A5080292021 @default.
- W2109474061 creator A5085843860 @default.
- W2109474061 creator A5088403406 @default.
- W2109474061 date "2004-10-26" @default.
- W2109474061 modified "2023-10-14" @default.
- W2109474061 title "Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction" @default.
- W2109474061 cites W1979030376 @default.
- W2109474061 cites W1981498546 @default.
- W2109474061 cites W1995426124 @default.
- W2109474061 cites W2044773944 @default.
- W2109474061 cites W2048047704 @default.
- W2109474061 cites W2048739403 @default.
- W2109474061 cites W2050285327 @default.
- W2109474061 cites W2056893352 @default.
- W2109474061 cites W2056976690 @default.
- W2109474061 cites W2090544953 @default.
- W2109474061 cites W2092314772 @default.
- W2109474061 cites W2097971039 @default.
- W2109474061 cites W2098780362 @default.
- W2109474061 cites W2100082183 @default.
- W2109474061 cites W2104787874 @default.
- W2109474061 cites W2118046716 @default.
- W2109474061 cites W2118651999 @default.
- W2109474061 cites W2127254785 @default.
- W2109474061 cites W2133217116 @default.
- W2109474061 cites W2135038122 @default.
- W2109474061 cites W2137534212 @default.
- W2109474061 cites W2139888542 @default.
- W2109474061 cites W2142119395 @default.
- W2109474061 cites W2166193862 @default.
- W2109474061 cites W2172025889 @default.
- W2109474061 cites W2174315288 @default.
- W2109474061 cites W2296998040 @default.
- W2109474061 cites W2323072331 @default.
- W2109474061 cites W2323458614 @default.
- W2109474061 cites W2326508838 @default.
- W2109474061 cites W2329306090 @default.
- W2109474061 cites W2585382523 @default.
- W2109474061 cites W3021063182 @default.
- W2109474061 cites W4245244523 @default.
- W2109474061 cites W4255009698 @default.
- W2109474061 cites W4293085726 @default.
- W2109474061 cites W52877415 @default.
- W2109474061 cites W59419314 @default.
- W2109474061 doi "https://doi.org/10.1161/01.cir.0000146819.43235.a9" @default.
- W2109474061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15492298" @default.
- W2109474061 hasPublicationYear "2004" @default.
- W2109474061 type Work @default.
- W2109474061 sameAs 2109474061 @default.
- W2109474061 citedByCount "346" @default.
- W2109474061 countsByYear W21094740612012 @default.
- W2109474061 countsByYear W21094740612013 @default.
- W2109474061 countsByYear W21094740612014 @default.
- W2109474061 countsByYear W21094740612015 @default.
- W2109474061 countsByYear W21094740612016 @default.
- W2109474061 countsByYear W21094740612017 @default.
- W2109474061 countsByYear W21094740612018 @default.
- W2109474061 countsByYear W21094740612019 @default.
- W2109474061 countsByYear W21094740612020 @default.
- W2109474061 countsByYear W21094740612021 @default.
- W2109474061 countsByYear W21094740612022 @default.
- W2109474061 countsByYear W21094740612023 @default.
- W2109474061 crossrefType "journal-article" @default.
- W2109474061 hasAuthorship W2109474061A5006688566 @default.
- W2109474061 hasAuthorship W2109474061A5008402827 @default.
- W2109474061 hasAuthorship W2109474061A5014449865 @default.
- W2109474061 hasAuthorship W2109474061A5018419311 @default.
- W2109474061 hasAuthorship W2109474061A5020758622 @default.
- W2109474061 hasAuthorship W2109474061A5022837719 @default.
- W2109474061 hasAuthorship W2109474061A5027213857 @default.
- W2109474061 hasAuthorship W2109474061A5028660133 @default.
- W2109474061 hasAuthorship W2109474061A5031560506 @default.
- W2109474061 hasAuthorship W2109474061A5037002715 @default.
- W2109474061 hasAuthorship W2109474061A5037320109 @default.
- W2109474061 hasAuthorship W2109474061A5054163944 @default.
- W2109474061 hasAuthorship W2109474061A5054830306 @default.
- W2109474061 hasAuthorship W2109474061A5064737068 @default.
- W2109474061 hasAuthorship W2109474061A5077729845 @default.
- W2109474061 hasAuthorship W2109474061A5080292021 @default.
- W2109474061 hasAuthorship W2109474061A5085843860 @default.
- W2109474061 hasAuthorship W2109474061A5088403406 @default.